ReNeuron Provides Business Update and Results Notification
Second Cohort of Phase 2a Study in Retinitis Pigmentosa Dosing Complete
LONDON, May 8, 2019 -- (Healthcare Sales & Marketing Network) -- ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, announced a year-end... Regenerative Medicine, Ophthalmology, Neurology ReNeuron Group, retinitis pigmentosa, stroke, stem cell
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Brain | Marketing | Neurology | Opthalmology | Pharmaceuticals | Retinitis Pigmentosa | Stem Cell Therapy | Stem Cells | Stroke | Study